Government-performed comparative drug studies are bad because the results not only affect Medicare but the private market as well, writes American Enterprise Institute fellow Scott Gottlieb in an op-ed for the Wall Street Journal. A provision for a new federal center to study the economics of drug choices (part of the State Children's Health Insurance Program) will give misleading results and the data will not be transparent, argues Gottlieb, drawing on past studies such as